212 related articles for article (PubMed ID: 36270990)
1. Global mapping of GalNAc-T isoform-specificities and O-glycosylation site-occupancy in a tissue-forming human cell line.
Nielsen MI; de Haan N; Kightlinger W; Ye Z; Dabelsteen S; Li M; Jewett MC; Bagdonaite I; Vakhrushev SY; Wandall HH
Nat Commun; 2022 Oct; 13(1):6257. PubMed ID: 36270990
[TBL] [Abstract][Full Text] [Related]
2. Probing polypeptide GalNAc-transferase isoform substrate specificities by in vitro analysis.
Kong Y; Joshi HJ; Schjoldager KT; Madsen TD; Gerken TA; Vester-Christensen MB; Wandall HH; Bennett EP; Levery SB; Vakhrushev SY; Clausen H
Glycobiology; 2015 Jan; 25(1):55-65. PubMed ID: 25155433
[TBL] [Abstract][Full Text] [Related]
3. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
Bagdonaite I; Abdurahman S; Mirandola M; Pasqual D; Frank M; Narimatsu Y; Joshi HJ; Vakhrushev SY; Salata C; Mirazimi A; Wandall HH
J Virol; 2024 Jun; 98(6):e0052424. PubMed ID: 38757972
[TBL] [Abstract][Full Text] [Related]
4. Probing the contribution of individual polypeptide GalNAc-transferase isoforms to the
Hintze J; Ye Z; Narimatsu Y; Madsen TD; Joshi HJ; Goth CK; Linstedt A; Bachert C; Mandel U; Bennett EP; Vakhrushev SY; Schjoldager KT
J Biol Chem; 2018 Dec; 293(49):19064-19077. PubMed ID: 30327431
[TBL] [Abstract][Full Text] [Related]
5. O-glycan initiation directs distinct biological pathways and controls epithelial differentiation.
Bagdonaite I; Pallesen EM; Ye Z; Vakhrushev SY; Marinova IN; Nielsen MI; Kramer SH; Pedersen SF; Joshi HJ; Bennett EP; Dabelsteen S; Wandall HH
EMBO Rep; 2020 Jun; 21(6):e48885. PubMed ID: 32329196
[TBL] [Abstract][Full Text] [Related]
6. Polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) isozyme surface charge governs charge substrate preferences to modulate mucin type O-glycosylation.
Ballard CJ; Paserba MR; Paul Daniel EJ; Hurtado-Guerrero R; Gerken TA
Glycobiology; 2023 Oct; 33(10):817-836. PubMed ID: 37555669
[TBL] [Abstract][Full Text] [Related]
7. Site-specific protein O-glycosylation modulates proprotein processing - deciphering specific functions of the large polypeptide GalNAc-transferase gene family.
Schjoldager KT; Clausen H
Biochim Biophys Acta; 2012 Dec; 1820(12):2079-94. PubMed ID: 23022508
[TBL] [Abstract][Full Text] [Related]
8. Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation.
Daniel EJP; Las Rivas M; Lira-Navarrete E; García-García A; Hurtado-Guerrero R; Clausen H; Gerken TA
Glycobiology; 2020 Oct; 30(11):910-922. PubMed ID: 32304323
[TBL] [Abstract][Full Text] [Related]
9. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family.
Bennett EP; Mandel U; Clausen H; Gerken TA; Fritz TA; Tabak LA
Glycobiology; 2012 Jun; 22(6):736-56. PubMed ID: 22183981
[TBL] [Abstract][Full Text] [Related]
10. An efficient approach for the characterization of mucin-type glycopeptides: the effect of O-glycosylation on the conformation of synthetic mucin peptides.
Hashimoto R; Fujitani N; Takegawa Y; Kurogochi M; Matsushita T; Naruchi K; Ohyabu N; Hinou H; Gao XD; Manri N; Satake H; Kaneko A; Sakamoto T; Nishimura S
Chemistry; 2011 Feb; 17(8):2393-404. PubMed ID: 21264968
[TBL] [Abstract][Full Text] [Related]
11. Site directed processing: role of amino acid sequences and glycosylation of acceptor glycopeptides in the assembly of extended mucin type O-glycan core 2.
Brockhausen I; Dowler T; Paulsen H
Biochim Biophys Acta; 2009 Oct; 1790(10):1244-57. PubMed ID: 19524017
[TBL] [Abstract][Full Text] [Related]
12. Site-specific
Goth CK; Tuhkanen HE; Khan H; Lackman JJ; Wang S; Narimatsu Y; Hansen LH; Overall CM; Clausen H; Schjoldager KT; Petäjä-Repo UE
J Biol Chem; 2017 Mar; 292(11):4714-4726. PubMed ID: 28167537
[TBL] [Abstract][Full Text] [Related]
13. Unexpected tolerance of glycosylation by UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase revealed by electron capture dissociation mass spectrometry: carbohydrate as potential protective groups.
Yoshimura Y; Matsushita T; Fujitani N; Takegawa Y; Fujihira H; Naruchi K; Gao XD; Manri N; Sakamoto T; Kato K; Hinou H; Nishimura S
Biochemistry; 2010 Jul; 49(28):5929-41. PubMed ID: 20540529
[TBL] [Abstract][Full Text] [Related]
14. Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells.
Schjoldager KT; Vakhrushev SY; Kong Y; Steentoft C; Nudelman AS; Pedersen NB; Wandall HH; Mandel U; Bennett EP; Levery SB; Clausen H
Proc Natl Acad Sci U S A; 2012 Jun; 109(25):9893-8. PubMed ID: 22566642
[TBL] [Abstract][Full Text] [Related]
15. Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins--towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation.
Daskalova SM; Radder JE; Cichacz ZA; Olsen SH; Tsaprailis G; Mason H; Lopez LC
BMC Biotechnol; 2010 Aug; 10():62. PubMed ID: 20735851
[TBL] [Abstract][Full Text] [Related]
16. The lectin domain of the polypeptide GalNAc transferase family of glycosyltransferases (ppGalNAc Ts) acts as a switch directing glycopeptide substrate glycosylation in an N- or C-terminal direction, further controlling mucin type O-glycosylation.
Gerken TA; Revoredo L; Thome JJ; Tabak LA; Vester-Christensen MB; Clausen H; Gahlay GK; Jarvis DL; Johnson RW; Moniz HA; Moremen K
J Biol Chem; 2013 Jul; 288(27):19900-14. PubMed ID: 23689369
[TBL] [Abstract][Full Text] [Related]
17. Site-specific O-glycosylation of N-terminal serine residues by polypeptide GalNAc-transferase 2 modulates human δ-opioid receptor turnover at the plasma membrane.
Lackman JJ; Goth CK; Halim A; Vakhrushev SY; Clausen H; Petäjä-Repo UE
Cell Signal; 2018 Jan; 42():184-193. PubMed ID: 29097258
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptide-preferring polypeptide GalNAc transferase 10 (ppGalNAc T10), involved in mucin-type O-glycosylation, has a unique GalNAc-O-Ser/Thr-binding site in its catalytic domain not found in ppGalNAc T1 or T2.
Perrine CL; Ganguli A; Wu P; Bertozzi CR; Fritz TA; Raman J; Tabak LA; Gerken TA
J Biol Chem; 2009 Jul; 284(30):20387-97. PubMed ID: 19460755
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the human polypeptide GalNAc-T1 and T13 paralogs.
Festari MF; Trajtenberg F; Berois N; Pantano S; Revoredo L; Kong Y; Solari-Saquieres P; Narimatsu Y; Freire T; Bay S; Robello C; Bénard J; Gerken TA; Clausen H; Osinaga E
Glycobiology; 2017 Jan; 27(2):140-153. PubMed ID: 27913570
[TBL] [Abstract][Full Text] [Related]
20. Mucin-type O-glycosylation and its potential use in drug and vaccine development.
Tarp MA; Clausen H
Biochim Biophys Acta; 2008 Mar; 1780(3):546-63. PubMed ID: 17988798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
